

# FINANCIAL REPORTING

Public Biotechnology Company



## ENGAGEMENT OVERVIEW

A global vaccine innovator faced significant challenges during a period of transition. High turnover and internal reorganization created resource gaps, while regulatory approvals triggered new vendor commercialization requirements. The company faced tight financial reporting deadlines and continuous inventory impairment analysis amid fluctuating demand. Alliance was engaged to stabilize operations, strengthen financial reporting, and support both R&D FP&A and manufacturing finance. The team streamlined month-end close processes, enhanced vendor accruals, implemented new inventory controls, and ensured compliance with SOX and audit requirements.

“

*Despite high turnover and reorganization, which created disruptions within the finance team, Alliance improved the efficiency of the month-end close process and provided crucial support during the transition from pre-commercial to commercial operations.*

”

## ALLIANCE SOLUTION

Alliance provided comprehensive accounting and finance support through:

01

### Close Efficiency

Improved FP&A close processes and ensured accurate monthly vendor accruals.

02

### Timely Reporting

Compiled and reviewed system reports to provide accurate budgets and forecasts.

03

### Process Enhancement

Developed templates and contract analysis for commercial vendors, improving accuracy of reporting and controls.

04

### Controls & Audit Support

Updated and developed inventory controls, prepared reconciliations, and coordinated with auditors for smooth reviews.

## CLIENT OUTCOMES

- Increased month-end close efficiency and accuracy across R&D and commercial operations.
- Strengthened vendor and inventory controls, ensuring compliance with SOX and audit requirements.
- Provided stability and expertise during a critical transition from pre-commercial to commercial operations.

[alliance]